Wikidata entity: Q420262
C₁₉H₁₈ClN₃O₅S (P274)
Quantities
| P4250 | defined daily dose | 20 |
| P2067 | mass | 435.066 |
| P3780 | active ingredient in | ... | Q29006683 (Xarelto) | Xarelto |
| P233 | canonical SMILES | String | C1COCC(=O)N1C2=CC=C(C=C2)N3CC(OC3=O)CNC(=O)C4=CC=C(S4)Cl | ??? |
| P373 | Commons category | String | Rivaroxaban | ??? |
| P366 | has use | ... | Q12140 (medication) | medication |
| P8224 | image of molecular model or crystal lattice model | CommonsMedia | http://commons.wikimedia.org/wiki/Special:FilePath/Rivaroxaban%20xtal%202005.png | ??? |
| P31 | instance of | ... | Q113145171 (type of chemical entity) | type of chemical entity |
| P2017 | isomeric SMILES | String | C1COCC(=O)N1C2=CC=C(C=C2)N3C[C@@H](OC3=O)CNC(=O)C4=CC=C(S4)Cl | ??? |
| P3493 | legal status (medicine) | ... | Q879952 (boxed warning) | boxed warning |
| P8026 | LiverTox likelihood score | ... | Q83284157 (LiverTox toxicity likelihood category B) | LiverTox toxicity likelihood category B |
| P2175 | medical condition treated | ... | Q41861 (arterial hypertension) | arterial hypertension |
| P2175 | medical condition treated | ... | Q190805 (heart disease) | heart disease |
| P2175 | medical condition treated | ... | Q189331 (heart arrhythmia) | heart arrhythmia |
| P2175 | medical condition treated | ... | Q220570 (pulmonary embolism) | pulmonary embolism |
| P2175 | medical condition treated | ... | Q261327 (thrombosis) | thrombosis |
| P2175 | medical condition treated | ... | Q377978 (thrombophlebitis) | thrombophlebitis |
| P2175 | medical condition treated | ... | Q593958 (transient cerebral isolation) | transient cerebral isolation |
| P2175 | medical condition treated | ... | Q1209150 (cerebral infarction) | cerebral infarction |
| P2175 | medical condition treated | ... | Q1506572 (atrial flutter) | atrial flutter |
| P2175 | medical condition treated | ... | Q1570013 (thrombophilia) | thrombophilia |
| P2175 | medical condition treated | ... | Q815819 (atrial fibrillation) | atrial fibrillation |
| P2175 | medical condition treated | ... | Q19000661 (congestive heart failure) | congestive heart failure |
| P2175 | medical condition treated | ... | Q1963588 (hematopoietic system disease) | hematopoietic system disease |
| P129 | physically interacts with | ... | Q423701 (coagulation factor X) | coagulation factor X |
| P3489 | pregnancy category | ... | Q3679261 (Australian pregnancy category C) | Australian pregnancy category C |
| P3489 | pregnancy category | ... | Q28123617 (US pregnancy category C) | US pregnancy category C |
| P636 | route of administration | ... | Q285166 (oral administration) | oral administration |
| P769 | significant drug interaction | ... | Q18216 (aspirin) | aspirin |
| P769 | significant drug interaction | ... | Q45050 (tenoxicam) | tenoxicam |
| P769 | significant drug interaction | ... | Q186969 (ibuprofen) | ibuprofen |
| P769 | significant drug interaction | ... | Q190016 (heparin) | heparin |
| P769 | significant drug interaction | ... | Q244408 (Diclofenac) | Diclofenac |
| P769 | significant drug interaction | ... | Q407617 (sertraline) | sertraline |
| P769 | significant drug interaction | ... | Q408471 (paroxetine) | paroxetine |
| P769 | significant drug interaction | ... | Q408676 (piroxicam) | piroxicam |
| P769 | significant drug interaction | ... | Q408801 (celecoxib) | celecoxib |
| P769 | significant drug interaction | ... | Q409192 ((RS)-ketoprofen) | (RS)-ketoprofen |
| P769 | significant drug interaction | ... | Q409231 (indomethacin) | indomethacin |
| P769 | significant drug interaction | ... | Q304088 (acenocoumarol) | acenocoumarol |
| P769 | significant drug interaction | ... | Q307088 (abciximab) | abciximab |
| P769 | significant drug interaction | ... | Q347941 (parecoxib) | parecoxib |
| P769 | significant drug interaction | ... | Q409236 (fluvoxamine) | fluvoxamine |
| P769 | significant drug interaction | ... | Q409672 ((RS)-citalopram) | (RS)-citalopram |
| P769 | significant drug interaction | ... | Q410237 (clopidogrel) | clopidogrel |
| P769 | significant drug interaction | ... | Q411932 ((S)-duloxetine) | (S)-duloxetine |
| P769 | significant drug interaction | ... | Q412050 (prostacyclin) | prostacyclin |
| P769 | significant drug interaction | ... | Q414028 (meloxicam) | meloxicam |
| P769 | significant drug interaction | ... | Q414462 (apixaban) | apixaban |
| P769 | significant drug interaction | ... | Q415366 (tirofiban) | tirofiban |
| P769 | significant drug interaction | ... | Q416232 (prasugrel) | prasugrel |
| P769 | significant drug interaction | ... | Q425207 (nabumetone) | nabumetone |
| P769 | significant drug interaction | ... | Q481757 (aceclofenac) | aceclofenac |
| P769 | significant drug interaction | ... | Q416485 (Streptokinase) | Streptokinase |
| P769 | significant drug interaction | ... | Q419890 ((±)-flurbiprofen) | (±)-flurbiprofen |
| P769 | significant drug interaction | ... | Q420542 (ticagrelor) | ticagrelor |
| P769 | significant drug interaction | ... | Q422244 (fluoxetine) | fluoxetine |
| P769 | significant drug interaction | ... | Q963093 (sulindac) | sulindac |
| P769 | significant drug interaction | ... | Q1215575 (naproxen) | naproxen |
| P769 | significant drug interaction | ... | Q2295855 (eptifibatide) | eptifibatide |
| P769 | significant drug interaction | ... | Q2465218 ((RS)-etodolac) | (RS)-etodolac |
| P769 | significant drug interaction | ... | Q2555245 ((RS)-fenoprofen) | (RS)-fenoprofen |
| P769 | significant drug interaction | ... | Q3563148 (vortioxetine) | vortioxetine |
| P769 | significant drug interaction | ... | Q898407 (venlafaxine) | venlafaxine |
| P769 | significant drug interaction | ... | Q3655338 (cangrelor) | cangrelor |
| P769 | significant drug interaction | ... | Q5984881 (ibrutinib) | ibrutinib |
| P769 | significant drug interaction | ... | Q1640947 (phenindione) | phenindione |
| P769 | significant drug interaction | ... | Q1644947 (tenecteplase) | tenecteplase |
| P769 | significant drug interaction | ... | Q1851701 (dalteparin) | dalteparin |
| P769 | significant drug interaction | ... | Q20817139 (iloprost) | iloprost |
| P769 | significant drug interaction | ... | Q20817252 (tinzaparin) | tinzaparin |
| P769 | significant drug interaction | ... | Q27077698 (fondaparinux) | fondaparinux |
| P769 | significant drug interaction | ... | Q45769835 (alteplase) | alteplase |
| P769 | significant drug interaction | ... | Q105969996 (enoxaparin) | enoxaparin |
| P769 | significant drug interaction | ... | Q110969665 (urokinase) | urokinase |
| P769 | significant drug interaction | ... | Q113368879 (rac-warfarin) | rac-warfarin |
| P3364 | stereoisomer of | ... | Q72506815 ((5R)-rivaroxaban) | (5R)-rivaroxaban |
| P279 | subclass of | ... | Q82236594 (5-chloro-N-({2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide) | 5-chloro-N-({2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide |
| P2868 | subject has role | ... | Q906280 (direct Xa inhibitor) | direct Xa inhibitor |
| P2275 | World Health Organisation international non-proprietary name | Monolingualtext | rivaroxaban | ??? |
Why not click here or view trends?
log id: 2327931